Ticker
ABCL

Price
7.31
Stock movement up
+0.40 (5.79%)
Company name
Abcellera Biologics Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
2.10B
Ent value
2.02B
Price/Sales
4.33
Price/Book
1.71
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
13.27
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-4.69%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2023-06-07
Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
May 24, 2023

iO Charts is a Seeking Alpha partner

AbCellera reported Q1 2023 results on May 4th. While it appears to have no clear catalyst to rise in the short term, see why I rate ABCL stock a Buy.
May 6, 2023

iO Charts is a Seeking Alpha partner

DIVIDENDS

ABCL does not pay dividends or no data was received
Loading...
AD

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E13.27
Price to OCF7.58
Price to FCF10.27
Price to EBITDA7.73
EV to EBITDA7.44

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales4.33
Price to Book1.71
EV to Sales4.17
AbCellera Biologics Inc. (NASDAQ:NASDAQ:ABCL) Q1 2023 Results Conference Call May 4, 2023 5:00 PM ETCompany ParticipantsTryn Stimart - Chief Legal and Compliance OfficerDr.
May 5, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
May 4, 2023

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count287.69M
EPS (TTM)0.50
FCF per share (TTM)0.65

Income statement

Loading...
Income statement data
Revenue (TTM)485.43M
Gross profit (TTM)418.99M
Operating income (TTM)218.19M
Net income (TTM)158.52M
EPS (TTM)0.50
EPS (1y forward)-0.65

Margins

Loading...
Margins data
Gross margin (TTM)86.31%
Operating margin (TTM)44.95%
Profit margin (TTM)32.66%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash386.54M
Net receivables103.41M
Total current assets1.03B
Goodwill47.81M
Intangible assets131.50M
Property, plant and equipment0.00
Total assets1.54B
Accounts payable14.83M
Short/Current long term debt82.26M
Total current liabilities118.32M
Total liabilities307.63M
Shareholder's equity1.23B
Net tangible assets1.05B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)277.36M
Capital expenditures (TTM)72.66M
Free cash flow (TTM)204.70M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity12.85%
Return on Assets10.29%
Return on Invested Capital12.80%
Cash Return on Invested Capital16.52%
Loading...
AD

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open6.97
Daily high7.40
Daily low6.94
Daily Volume4.58M
All-time high53.20
1y analyst estimate28.33
Beta-0.09
EPS (TTM)0.50
Dividend per share-
Ex-div date-
Next earnings date7 Aug 2023

Downside potential

Loading...
Downside potential data
ABCLS&P500
Current price drop from All-time high-86.26%-10.71%
Highest price drop-89.36%-56.47%
Date of highest drop9 May 20239 Mar 2009
Avg drop from high-68.83%-11.53%
Avg time to new high125 days13 days
Max time to new high592 days1805 days
Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
May 3, 2023

iO Charts is a Seeking Alpha partner

AbCellera is pledging to discover promising antibodies for its clients and bring them to the clinic faster than anybody else. Read more about ABCL and the challenges it faces.
March 24, 2023

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ABCL (Abcellera Biologics Inc) company logo
Marketcap
2.10B
Marketcap category
Mid-cap
Description
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Employees
495
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
Today, we take a deeper look at AbCellera Biologics whose Covid revenue stream is fading fast as the pandemic ends. Click here to see our take on ABCL stock.
March 23, 2023

iO Charts is a Seeking Alpha partner

Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
March 22, 2023

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
The following slide deck was published by AbCellera Biologics Inc.
February 22, 2023
AbCellera Biologics Inc. (NASDAQ:NASDAQ:ABCL) Q4 2022 Earnings Conference Call February 21, 2023 5:00 PM ETCompany ParticipantsTryn Stimart - Chief Legal and Compliance OfficerCarl Hansen -...
February 22, 2023
Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
February 21, 2023
Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
February 20, 2023
In this article, I will provide my valuation model for AbCellera, building on an article I wrote over a year ago. See why I'm fervently bullish on ABCL stock.
January 5, 2023
Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
December 15, 2022
Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
December 1, 2022
Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
November 30, 2022
Get the latest news and real-time alerts from AbCellera Biologics Inc. (ABCL) stock at Seeking Alpha.
November 16, 2022
AbCellera Biologics has multiple high-value opportunities that should become clear in the next few years. Find out why I'm confident in the long-term return potential of ABCL.
November 9, 2022
iO Charts is a Seeking Alpha partnerNext page